@article{PfuetznerStandlStrotmannetal.2006,
  author    = {Andreas Pf{\"u}tzner and Eberhard Standl and Hermann-Josef Strotmann and Jan Schulze and Cloth Hohberg and Georg L{\"u}bben and Sabine Pahler and Thomas Sch{\"o}ndorf and Thomas Forst},
  title     = {Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus},
  series   = {Clinical Chemistry and Laboratory Medicine},
  volume    = {44},
  number    = {5},
  publisher = {de Gruyter},
  address   = {Berlin},
  issn      = {1437-4331},
  doi       = {10.1515/CCLM.2006.108},
  url       = {https://nbn-resolving.org/urn:nbn:de:hbz:1044-opus-28723},
  pages     = {556 -- 560},
  year      = {2006},
  abstract  = {Background: Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP). Methods: This cross-sectional study attempted to analyze the association of hsCRP levels with insulin resistance, β-cell dysfunction and macrovascular disease in 4270 non-insulin-treated patients with type 2 diabetes [2146 male, 2124 female; mean age ±SD, 63.9±11.1years; body mass index (BMI) 30.1±5.5kg/m2; disease duration 5.4±5.6years; hemoglobin A1c (HbA1c) 6.8±1.3\%]. It consisted of a single morning visit with collection of a fasting blood sample. Observational parameters included several clinical scores and laboratory biomarkers. Results: Stratification into cardiovascular risk groups according to hsCRP levels revealed that 934 patients had low risk (hsCRP <1mg/L), 1369 patients had intermediate risk (hsCRP 1–3mg/L), 1352 patients had high risk (hsCRP >3–10mg/L), and 610 patients had unspecific hsCRP elevation (>10mg/L). Increased hsCRP levels were associated with other indicators of diabetes-related cardiovascular risk (homeostatic model assessment, intact proinsulin, insulin, BMI, β-cell dysfunction, all p<0.001), but showed no correlation with disease duration or glucose control. The majority of the patients were treated with diet (34.1\%; hsCRP levels 2.85±2.39mg/L) or metformin monotherapy (21.1\%; 2.95±2.50mg/L hsCRP). The highest hsCRP levels were observed in patients treated with sulfonylurea (17.0\%; 3.00±2.43mg/L). Conclusions: Our results indicate that hsCRP may be used as a cardiovascular risk marker in patients with type 2 diabetes mellitus and should be evaluated in further prospective studies.},
  language  = {en}
}